Safety and Efficacy with Twice Daily Brinzolamide 1% / Brimonidine 0.2% (SIMBRINZA) as an Adjunctive Therapy to Travoprost 0.004% / Timolol 0.5% (DUOTRAV)

1. Subjects 18 years of age or older, of any race, diagnosed with either open-angle glaucoma (including pseudo exfoliation or pigment dispersion glaucoma) or ocular hypertension
2. Subjects currently on treatment with Travoprost 0.004% / Timolol 0.5% prescribed as approved in the country, on morning or evening dosing for at least 28 days prior to screening and that in the opinion of the Investigator may benefit from further IOP lowering
3. Qualifying mean IOP measurements at both the Eligibility 1 and Eligibility 2 visits, in at least 1 eye (the same eye(s) * 19 and * 28 mmHg at 9:00 while on a Travoprost 0.004% / Timolol 0.5% solution)
4. Must be able to understand and sign an informed consent form that has been approved by an Institutional Review Board/Ethics Committee
5. Willing and able to attend all study visits

1. Women of childbearing potential (WOCBP), defined as all women who are not postmenopausal for at least 1 year or less than 6 weeks since sterilization, are excluded from participation if: a. they are currently pregnant, or // b. have a positive result on the urine pregnancy test at Screening, or // c. intend to become pregnant during the study period, or // d. are breast-feeding, or // e. are not in agreement to use adequate birth control methods to prevent pregnancy throughout the study.
All women of childbearing potential are required to use adequate birth control methods which are summarized as follows: a. Total abstinence (when this is in line with the preferred and usual lifestyle of the subject). Periodic abstinence (eg, calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception. // b. Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least 6 weeks before Baseline. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment. // c. Male sterilization (at least 6 months prior to Baseline). For female subjects in the study, the vasectomized male partner should be the sole partner for that subject. // d. Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate < 1%), for example hormone vaginal ring or transdermal hormone contraception. // e. Placement of an intrauterine device (IUD) or intrauterine system (IUS).;2. Subjects with any form of glaucoma other than open-angle glaucoma or ocular hypertension.
3. Subjects with central cornea thickness (CCT) greater than 620 *m as measured by pachymetry in either eye.
4. Subjects with Schaffer angle Grade < 2 in either eye, as measured by gonioscopy (extreme narrow angle with complete or partial closure).
5. Subjects with cup/disc ratio greater than 0.80 (horizontal or vertical measurement) in either eye.
6. Subjects with severe central visual field loss in either eye or field loss threatening fixation in either eye.
7. Subjects with chronic, recurrent or severe inflammatory eye disease (eg, scleritis, uveitis, herpes keratitis) in either eye.
8. Subjects with ocular trauma in either eye within the past 6 months prior to the Screening visit.
9. Subjects with ocular infection or ocular inflammation in either eye within the past 3 months prior to the Screening visit.
10. Subjects with clinically significant or progressive retinal disease such as retinal degeneration, diabetic retinopathy, or retinal detachment in either eye.
11. Subjects with best-corrected visual acuity score worse than 55 ETDRS letters (equivalent to approximately 20/80 Snellen, 0.60 logMAR or 0.25 decimal) in either eye.
12. Subjects with other ocular pathology (including severe dry eye) in either eye that may, in the opinion of the Investigator, preclude the safe administration of any study medication.
13. Subjects with intraocular surgery in either eye within the past 6 months prior to the Screening visit.
14. Subjects with ocular laser surgery in either eye within the past 3 months prior to the Screening visit.
15. Subjects with any abnormality preventing reliable applanation tonometry in either eye.
16. Any other conditions including severe illness which would make the subject, in the opinion of the Investigator, unsuitable for the study.
17. Subjects with recent (within 4 weeks of the Eligibility 1 Visit) use of high dose (> 1 gm daily) salicylate therapy.
18. Subjects with history of active, severe, unstable or uncontrolled cardiovascular (eg, coronary insufficiency, hypertension, Raynaud*s phenomenon, orthostatic hypotension, thromboangiitis obliterans), cerebrovascular (eg, cerebral insufficiency), hepatic, or renal disease that would preclude the safe administration of a topical alpha-adrenergic agonist or carbonic anhydrase inhibitor in the opinion of the Investigator.
19. Subjects with current or anticipated treatment with any psychotropic drugs that augment an adrenergic response (eg, desipramine, amitriptyline).
20. Concurrent use of a monoamine oxidase inhibitor.
21. Study participants with asthma, history of asthma, or severe chronic obstructive pulmonary disease.
22. Therapy with another investigational agent within 30 days prior to the Screening Visit.
23. Subjects with less than 30 days stable dosing regimen before the Screening Visit of any medications (excluding the IOP lowering treatments) or substances administered by any route and used on a chronic basis that may affect IOP (eg, *-adrenergic blocking agents). The dosing regimen of these medications should not change during the study.
24. Subjects with hypersensitivity to alpha-adrenergic agonist drugs, topical or oral CAIs, PGAs, timolol, sulfonamide derivatives, or to any component of the study medications in the opinion of the Investigator.
25. Use of any additional topical or systemic ocular hypotensive medication in either eye during the study.
26. Subjects who cannot safely discontinue all glucocorticoids administered by any route prior to the Eligibility Visit 1 and continue to not use during the study. Steroid washout duration: a. Chronic therapy * 4 weeks // b. Intermittent therapy - 2 weeks.
27. Mean IOP > 28 mmHg at any time point during the Screening/Eligibility Phase.